February 12, 2008 - Accuray Inc. today announced that two- and thee-year studies on its Cyberknife radiosurgery has shown no side effects on men treated for prostate cancer and prostate specific antigen (PSA) levels showed sustained reduction during the studies.

These findings were shared at the 7th Annual CyberKnife Users' Meeting, which was held Jan. 23-27, 2008 in Scottsdale, AR.

"We're pleased that so much progress has been made demonstrating positive outcomes using the CyberKnife System as a noninvasive treatment option for prostate cancer, including durable PSA level reductions up to three years post-treatment," said Michael Santoro, M.D., attending urologist at Winthrop University Hospital's CyberKnife Radiosurgery Center.

Additionally lung cancer treatment using the CyberKnife System continued to draw a large amount of interest among the attendees with the presentation of experiences from clinicians around the world treating patients with lung tumors successfully with the CyberKnife System, said the company. During the meeting, a majority of the institutions present expressed strong interest in the prospective clinical study that is being led by M. D. Anderson Cancer Center in Houston comparing treatment outcomes with the CyberKnife System versus surgery in early-stage, operable lung cancer, according to Accuray.

Along with the enthusiasm around CyberKnife extracranial treatment results, the system remains a widely accepted tool in the treatment of brain tumors said the company. A data comparison of patients with acoustic tumors, treated by either CyberKnife or Gamma Knife radiosurgery demonstrated superior hearing preservation in the patients treated with the CyberKnife System.

According to the company, emerging CyberKnife treatment applications highlighted at the meeting demonstrated promising results treating patients with breast cancer, bone cancer, kidney cancer and various pain syndromes.

For more information: www.accuray.com


Related Content

News | Artificial Intelligence

May 14, 2024 — Elekta announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high ...

Time May 14, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Insurance expansions under the Affordable Care Act (ACA) were linked with an increase in patients ...

Time May 10, 2024
arrow
News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
Subscribe Now